Search

Your search keyword '"Khan, Muhammad Shahzeb"' showing total 1,620 results
Start Over Author "Khan, Muhammad Shahzeb"
1,620 results on '"Khan, Muhammad Shahzeb"'

215. The Interplay between Online Consumer Reviews and Firms Interventions from Four Stakeholders' Perspectives.

Author

Ghias, Saqib, Khan, Muhammad Shahzeb, Qureshi, Muhammad Azeem, Buledi, Muhammad Irshd, and Jaleel, Ahsan Ahmed

Abstract

This study presents the perspectives of the travel industry stakeholders, namely travellers, potential tourists, hospitality businesses, and travel agents. There is little literature available that covers the perspectives of all these stakeholders. The study tries to understand the preference of travellers, problems faced by them, the response of hospitality businesses on reviews posted by travellers, and the viewpoint of travel agents. A purposive sampling technique was used to select respondents for semi-structured interviews. A total of seven semi-structured interviews were conducted online to understand better the perspectives on the study topic. Thematic analysis was applied to the interview data and several themes related to each stakeholder emerged. The main themes include online presence, travellers' preference, hospitality businesses' response, and social media interaction. Travellers usually expect neat and clean rooms, washrooms, comfortable beds, and food. They expect services in accordance to the fee they pay. Hospitality businesses have dedicated staff to respond to every comment they receive. More positive reviews increase the chances of guest inflow and vice versa. There are no websites in Pakistan to review the travel agents' services, however, they are reviewed mostly on social media pages. These travel agents provide a one-stop solution to their guests and have to be very vigilant in addressing any inconvenience voiced by their customers. This research provides insights to all the stakeholders involved in the industry and gives valuable pointers to improve their services. [ABSTRACT FROM AUTHOR]

Published
2023

216. Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum

Author

Filbey, Lynaea, primary, Zhu, Jie Wei, additional, D’Angelo, Francesca, additional, Thabane, Lehana, additional, Khan, Muhammad Shahzeb, additional, Lewis, Eldrin, additional, Patel, Manesh R, additional, Powell-Wiley, Tiffany, additional, Miranda, J Jaime, additional, Zuhlke, Liesl, additional, Butler, Javed, additional, Zannad, Faiez, additional, and Van Spall, Harriette G C, additional

Published
2023
Full Text
View/download PDF

217. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Author

Khan, Muhammad Shahzeb, primary, Butler, Javed, additional, Anker, Stefan D., additional, Filippatos, Gerasimos, additional, Ferreira, João Pedro, additional, Pocock, Stuart J., additional, Januzzi, James L., additional, Piña, Ileana L., additional, Böhm, Michael, additional, Ponikowski, Piotr, additional, Verma, Subodh, additional, Brueckmann, Martina, additional, Vedin, Ola, additional, Zeller, Cordula, additional, Zannad, Faiez, additional, and Packer, Milton, additional

Published
2023
Full Text
View/download PDF

219. Albuminuria and Heart Failure

Author

Khan, Muhammad Shahzeb, primary, Shahid, Izza, additional, Anker, Stefan D., additional, Fonarow, Gregg C., additional, Fudim, Marat, additional, Hall, Michael E., additional, Hernandez, Adrian, additional, Morris, Alanna A., additional, Shafi, Tariq, additional, Weir, Matthew R., additional, Zannad, Faiez, additional, Bakris, George L., additional, and Butler, Javed, additional

Published
2023
Full Text
View/download PDF

221. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction

Author

Sreenivasan, Jayakumar, primary, Malik, Aaqib, additional, Khan, Muhammad Shahzeb, additional, Lloji, Amanda, additional, Hooda, Urvashi, additional, Aronow, Wilbert S., additional, Lanier, Gregg M., additional, Pan, Stephen, additional, Greene, Stephen J., additional, Murad, M. Hassan, additional, Michos, Erin D., additional, Cooper, Howard A., additional, Gass, Alan, additional, Gupta, Rahul, additional, Desai, Nihar R., additional, Mentz, Robert J., additional, Frishman, William H., additional, and Panza, Julio A., additional

Published
2022
Full Text
View/download PDF

227. Ag modified ZnO microsphere synthesis for efficient sonophotocatalytic degradation of organic pollutants and CO2 conversion

Author

Khan, Muhammad Farooq, primary, Bakhtiar, Syed ul Hasnain, additional, Zada, Amir, additional, Raziq, Fazal, additional, Saleemi, Hassan Anwar, additional, Khan, Muhammad Shahzeb, additional, Muhammad Ismail, Pir, additional, Alguno, Arnold C., additional, Capangpangan, Rey Y., additional, Ali, Asad, additional, Hayat, Salman, additional, Ali, Sharafat, additional, Ismail, Ahmed, additional, and Zahid, Muhammad, additional

Published
2022
Full Text
View/download PDF

228. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced

Author

Anker, Stefan D., primary, Khan, Muhammad Shahzeb, additional, Butler, Javed, additional, Ofstad, Anne Pernille, additional, Peil, Barbara, additional, Pfarr, Egon, additional, Doehner, Wolfram, additional, Sattar, Naveed, additional, Coats, Andrew J. S., additional, Filippatos, Gerasimos, additional, Ferreira, João Pedro, additional, Zannad, Faiez, additional, Pocock, Stuart, additional, and Packer, Milton, additional

Published
2022
Full Text
View/download PDF

231. Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency

Author

KHAN, MUHAMMAD SHAHZEB, primary, ANKER, STEFAN D., additional, FRIEDE, TIM, additional, JANKOWSKA, EWA A., additional, METRA, MARCO, additional, PIÑA, ILEANA L, additional, COATS, ANDREW JS, additional, ROSANO, GIUSEPPE, additional, ROUBERT, BERNARD, additional, GOEHRING, UDO-MICHAEL, additional, DORIGOTTI, FABIO, additional, COMIN-COLET, JOSEP, additional, VANVELDHUISEN, DIRK J, additional, FILIPPATOS, GERASIMOS S., additional, PONIKOWSKI, PIOTR, additional, and BUTLER, JAVED, additional

Published
2022
Full Text
View/download PDF

238. Lead In drinking water: Adsorption method and role of zeolitic imidazolate frameworks for its remediation: A review

Author

Ahmad, Khalil, primary, Shah, Habib-ur-Rehman, additional, Khan, Muhammad Shahzeb, additional, Iqbal, Amjad, additional, Potrich, Erich, additional, Amaral, Larissa Souza, additional, Rasheed, Sidra, additional, Nawaz, Haq, additional, Ayub, Asif, additional, Naseem, Khalida, additional, Muhammad, Ali, additional, Yaqoob, Muhammad Rashid, additional, and Ashfaq, Muhammad, additional

Published
2022
Full Text
View/download PDF

243. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.

Author

Khan, Muhammad Shahzeb, Khan, Muhammad Shahzeb, Shahid, Izza, Asad, Nava, Greene, Stephen J, Khan, Safi U, Doukky, Rami, Metra, Marco, Anker, Stefan D, Filippatos, Gerasimos S, Fonarow, Gregg C, Butler, Javed, Khan, Muhammad Shahzeb, Khan, Muhammad Shahzeb, Shahid, Izza, Asad, Nava, Greene, Stephen J, Khan, Safi U, Doukky, Rami, Metra, Marco, Anker, Stefan D, Filippatos, Gerasimos S, Fonarow, Gregg C, and Butler, Javed

Abstract

AimsDiscontinuation or non-publication of trials may hinder scientific progress and violates the commitment made to research participants. We sought to identify the prevalence of discontinuation and non-publication of heart failure (HF) clinical trials.Methods and resultsWe conducted a cross-sectional search of ClinicalTrials.gov to identify all completed and discontinued HF clinical trials. We limited our search to only include trials that were completed by 31 December 2017. Trials were investigated to identify reasons for discontinuation. Informative termination was defined as trial termination due to safety or efficacy concerns. Data pertaining to the trial phase, funding, intervention, enrolment, and trial completion date were extracted for each trial. A total of 572 trials were included. Of these, 21% (n = 118) were discontinued before completion. Patient accrual was the most frequently cited reason (n = 42; 36%) for trial discontinuation, followed by informative termination (n = 16; 14%) and funding (n = 14; 12%). Overall, 24 780 patients were enrolled in trials that were terminated. Of trials that were completed and not terminated, nearly one-third (n = 131/454; 29%) were not published. Seventy-nine (24%) trials were published within 12 months, 192 (59%) within 24 months, and 252 (78%) trials within 36 months.ConclusionsDiscontinuation and non-publication of HF trials is common. This raises ethical concerns towards participants who volunteer for research and are exposed to potential risks, inconvenience, and discomfort without furthering scientific progress.

Published
2021

244. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.

Author

Khan, Muhammad Shahzeb, Khan, Muhammad Shahzeb, Khan, Muhammad Arbaz Arshad, Irfan, Simra, Siddiqi, Tariq Jamal, Greene, Stephen J, Anker, Stefan D, Sreenivasan, Jayakumar, Friede, Tim, Tahhan, Ayman Samman, Vaduganathan, Muthiah, Fonarow, Gregg C, Butler, Javed, Khan, Muhammad Shahzeb, Khan, Muhammad Shahzeb, Khan, Muhammad Arbaz Arshad, Irfan, Simra, Siddiqi, Tariq Jamal, Greene, Stephen J, Anker, Stefan D, Sreenivasan, Jayakumar, Friede, Tim, Tahhan, Ayman Samman, Vaduganathan, Muthiah, Fonarow, Gregg C, and Butler, Javed

Abstract

AimsThis study aimed to investigate the reporting of subgroup analyses in heart failure (HF) randomized controlled trials (RCTs) and to determine the strength and credibility of subgroup claims.Methods and resultsAll primary HF RCTs published in nine high-impact journals from 1 January 2008 to 31 December 2017 were included. Multivariable regression analysis was used to identify factors that may favour the reporting of results in specific subgroups. Strength of the subgroup effect claimed was classified into (i) strong, (ii) likely, or (iii) suggestive. Credibility of subgroup claim was scored using a pre-specified 10 pointer criteria. Of the 261 HF RCTs studied, 107 (41%) reported subgroup analyses. Twenty-five (23%) RCTs claimed a subgroup effect for the primary outcome of which six (24%) made a strong claim, eight (32%) claimed a likely effect, and 11 (44%) suggested a possible subgroup effect. Seven of the 25 RCTs did not employ interaction testing for subgroup claims of the primary outcome. Three out of 10 pre-specified credibility criteria were satisfied by half of the trials. Fourteen trials justified the choice of subgroups, and 10 explicitly stated they were underpowered to detect differences within subgroups. Source of funding did not influence the frequency of reporting subgroup analyses (OR 0.53, 95% CI 0.78-3.62, P = 0.52).ConclusionsAppropriate credibility criteria were rarely met even by HF RCTs that held strong subgroup claims. Subgroup analyses should be pre-specified, be adequately powered, present interaction terms, and be replicated in independent data before being integrated into clinical decision making.

Published
2021

246. Kidney involvement in transthyretin cardiac amyloidosis – Role of urinary albumin to creatinine ratio and need for further evidence generation.

Author

Khan, Muhammad Shahzeb, Sperry, Brett W., and Butler, Javed

Subjects
*CARDIAC amyloidosis, *TRANSTHYRETIN, *KIDNEYS, *ALBUMINS, *GLUCAGON-like peptide-1 receptor, *CREATININE
Abstract

This article discusses the prevalence and implications of albuminuria in transthyretin cardiac amyloidosis (ATTR-CA), a condition that is often under-recognized as a cause of heart failure. The study found that almost half of the patients with ATTR-CA had albuminuria, which is associated with an increased risk of mortality. The findings suggest that albuminuria can be a useful risk marker in patients with ATTR-CA and should be considered in clinical practice and trials. Further research is needed to understand the mechanisms behind kidney involvement in ATTR-CA and to explore potential treatments for albuminuria in these patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results